ストックスクリーナーアプリを入手
27.62
3.91%
1.04
アフターアワーズ：
27.10
-0.52
-1.88%
前日終値:
$26.58
開ける：
$26.17
24時間の取引高:
3.64M
Relative Volume:
1.49
時価総額：
$3.49B
収益：
$715.22M
当期純損益:
$-250.10M
株価収益率:
-13.61
EPS:
-2.03
ネットキャッシュフロー:
$-205.58M
1週間 パフォーマンス:
+13.52%
1か月 パフォーマンス:
+38.72%
6か月 パフォーマンス:
+0.80%
1年 パフォーマンス:
-23.32%
1日の値動き範囲:
$26.05
$27.85
1週間の範囲:
$23.75
$27.85
52週間の値動き範囲:
$16.10
$41.94
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
名前
Apellis Pharmaceuticals Inc
セクター
電話
617-977-5700
住所
100 FIFTH AVENUE, WALTHAM, KY
APLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
27.62 | 3.36B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-09 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-05-09 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-17 | ダウングレード | Goldman | Buy → Neutral |
| 2024-11-21 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-16 | 開始されました | William Blair | Outperform |
| 2024-05-31 | 開始されました | Piper Sandler | Neutral |
| 2024-02-05 | アップグレード | Jefferies | Hold → Buy |
| 2023-12-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-02 | 開始されました | Mizuho | Neutral |
| 2023-10-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-15 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 繰り返されました | Citigroup | Buy |
| 2023-08-03 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-08-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-01-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-19 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-17 | 再開されました | Stifel | Buy |
| 2022-04-14 | ダウングレード | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-29 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-09-10 | 繰り返されました | Credit Suisse | Neutral |
| 2021-09-10 | 繰り返されました | Needham | Buy |
| 2021-09-10 | 繰り返されました | Oppenheimer | Outperform |
| 2021-09-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-08-19 | 開始されました | Jefferies | Buy |
| 2021-08-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-16 | 開始されました | Goldman | Buy |
| 2020-11-19 | 開始されました | Needham | Buy |
| 2020-09-01 | 開始されました | Stifel | Buy |
| 2020-07-20 | 開始されました | ROTH Capital | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Neutral |
| 2020-04-01 | 開始されました | Raymond James | Strong Buy |
| 2020-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-11 | アップグレード | Wedbush | Underperform → Neutral |
| 2020-01-07 | 開始されました | SVB Leerink | Mkt Perform |
| 2019-12-19 | 開始されました | BofA/Merrill | Buy |
| 2019-11-22 | 開始されました | Wedbush | Underperform |
| 2019-11-05 | 開始されました | Credit Suisse | Neutral |
| 2019-08-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-07-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 開始されました | Robert W. Baird | Outperform |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-07-30 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-04-12 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Apellis Pharmaceuticals Inc (APLS) 最新ニュース
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli’s New Approval (APLS) - Seeking Alpha
Signal strength of Apellis Pharmaceuticals Inc. stock in tech scannersJuly 2025 Summary & Daily Stock Momentum Reports - Newser
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target - MSN
Watch for Trend Continuation in Apellis Pharmaceuticals Inc. Next Week2025 Major Catalysts & Risk Controlled Swing Trade Alerts - beatles.ru
Apellis Pharmaceuticals (APLS) Surges 10.27% on FDA Approval Momentum and Strategic Deals - AInvest
FDA Approval and Strategic Deals Drive Apellis Pharmaceuticals’ Stock Higher for the Week - Insider Monkey
Apellis Pharmaceuticals' Stock Surges 27.70% This Week Following FDA Approval, Q2 2025 Financial Results, and Capped Royalty Purchase Agreements - AInvest
Published on: 2025-08-12 03:12:35 - beatles.ru
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $20 to $57 - 富途牛牛
11 Best Short-Term Stocks to Invest in - Insider Monkey
Apellis wins FDA label expansion for Empaveli in rare kidney disorders - MSN
Fierce Biotech Layoff Tracker 2025: Tune, Bicycle let go of 25% of staff - Fierce Biotech
Apellis Pharmaceuticals' Empaveli Faces Market Challenges and Physician Preferences - AInvest
Hold Rating for Apellis Pharmaceuticals’ Empaveli Amid Market Challenges and Physician Preferences - TipRanks
Apellis Pharmaceuticals (APLS) Sees Target Price Raised by Citig - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2025 Earnings Call Transcript - Insider Monkey
Apellis Pharmaceuticals’ Earnings Call: A Balanced Outlook - TipRanks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS) and Akero Therapeutics (AKRO) - The Globe and Mail
Published on: 2025-08-04 22:37:11 - beatles.ru
Why Apellis Pharmaceuticals Shares Are Gaining Attention - TipRanks
Apellis Pharmaceuticals Inc. Stock Analysis and ForecastInvest smarter with actionable stock recommendations - Jammu Links News
Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug - MSN
Apellis’ EMPAVELI Approved by FDA for Rare Kidney Diseases - MSN
When is Apellis Pharmaceuticals Inc. stock expected to show significant growthBuild a portfolio with strong long-term growth - Jammu Links News
How many analysts rate Apellis Pharmaceuticals Inc. as a “Buy”Exceptional profit potential - Jammu Links News
What makes Apellis Pharmaceuticals Inc. stock price move sharplyDiscover undervalued stocks ready to soar - Jammu Links News
Is Apellis Pharmaceuticals Inc. a growth stock or a value stockFree Stock Movement Tracking - Jammu Links News
How strong is Apellis Pharmaceuticals Inc. company’s balance sheetBuild wealth steadily with proven investment techniques - Jammu Links News
How volatile is Apellis Pharmaceuticals Inc. stock compared to the marketAchieve breakthrough growth with proven strategies - Jammu Links News
What analysts say about Apellis Pharmaceuticals Inc. stockConsistent triple-digit returns - Jammu Links News
What catalysts could drive Apellis Pharmaceuticals Inc. stock higher in 2025High-octane investment gains - Jammu Links News
What drives Apellis Pharmaceuticals Inc. stock priceCapitalize on market trends before they peak - Jammu Links News
What institutional investors are buying Apellis Pharmaceuticals Inc. stockFree Stock Movement Tracking - Jammu Links News
Why is Apellis Pharmaceuticals Inc. stock attracting strong analyst attentionUnlock exclusive stock market forecasts - Jammu Links News
How does Apellis Pharmaceuticals Inc. generate profit in a changing economyUnlock powerful portfolio optimization tools - Jammu Links News
What are Apellis Pharmaceuticals Inc. company’s key revenue driversBuild a portfolio that stands the test of time - Jammu Links News
Apellis Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Apellis Pharmaceuticals: Navigating Q2 Earnings and Building a Complement-Driven Ophthalmology Powerhouse - AInvest
What are the latest earnings results for Apellis Pharmaceuticals Inc.Free Stock Target Finder For Fast Growth - jammulinksnews.com
Apellis Pharmaceuticals (APLS) Stock Forecast and Price Target 2025 - MarketBeat
Apellis Pharmaceuticals: The Picture Becomes Clearer (NASDAQ:APLS) - Seeking Alpha
Apellis Pharmaceuticals Surges 17.6% on Higher Price Target from Scotiabank - AInvest
Apellis (APLS) Price Target Raised as Market Stabilizes - GuruFocus
RBC Capital Raises Price Target for Apellis Pharmaceuticals (APLS) | APLS Stock News - GuruFocus
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $19 to $57 - 富途牛牛
Raymond James Adjusts Price Target for Apellis (APLS) After Q2 E - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Surges 25% Yet Its Low P/S Is No Reason For Excitement - 富途牛牛
APLS: Cantor Fitzgerald Raises Price Target for Apellis Pharmace - GuruFocus
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say - MSN
Analyst Raymond James Lowers Price Target for Apellis Pharmaceuticals (APLS) | APLS Stock News - GuruFocus
Apellis: Raymond James Maintains Outperform, PT Down to $50 - AInvest
Apellis Pharmaceuticals Inc (APLS) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
1.56%
大文字化:
|
ボリューム (24 時間):